Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chlorothiazide + furosemide
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination diuretic therapy that pairs chlorothiazide, a thiazide diuretic, with furosemide, a loop diuretic. Each medication works at different segments of the nephron to produce a synergistic diuretic effect, known as sequential nephron blockade. This combination is particularly useful in patients with refractory edema who have become resistant to loop diuretics alone, and for conditions requiring enhanced diuresis.
- Other names
- furosemide + hydrochlorothiazide
02
Targets
SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)NKCC2 (Sodium-potassium-chloride cotransporter 2)CA (Carbonic anhydrase)
Beyond the preview
Go deeper on chlorothiazide + furosemide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chlorothiazide + furosemide.